In patients with KRASG12C-mutated NSCLC previously treated with platinum-based chemotherapy and checkpoint inhibitor therapy, adagrasib showed an objective response of 42.9%. Tumor shrinkage of any magnitude was observed in 79.5% patients (A). Intracranial tumor shrinkage was also seen (B). The median duration of response was...
In chemotherapy-naïve, PD-L1-positive (tumour proportion score ≥1%) patients with locally advanced or metastatic NSCLC, tiragolumab plus atezolizumab showed a significant improvement in both objective response rate (ORR) and progression-free survival (PFS), with a stratified hazard ratio 0·57 [95% CI 0·37–0·90], p=0·015. The combination was well tolerated, with...
n patients with newly diagnosed IDH1-mutated AML who were ineligible for intensive induction therapy, Ivosidenib/Azacitidine combination showed significantly longer EFS compared to Azacitidine at a median follow-up of 12.4 months. The median OS was 24.0 months with Ivosidenib/Azacitidine and 7.9 months with Azacitidine. Febrile neutropenia and...
In patients with platinum-sensitive, recurrent ovarian cancer previously treated with at least two platinum-based regimens, Fuzuloparib as a maintenance therapy showed a significantly improved progression-free survival compared with placebo, regardless of germline BRCA 1/2 mutation. (Ref: Li N et al. J Clin Oncol. April 11, 2022) #oncologyresearch #clinicaldevelopment https://www.linkedin.com/feed/update/urn:li:activity:6923581090574000128...
Indolent MCL patients treated with frontline ibrutinib plus rituximab showed an overall response of 84% after 12 cycles of treatment, with 80% of patients experiencing a CR. Undetectable MRD in the peripheral blood was achieved in 87% of patients. The estimated PFS at 36 months...
In patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane, the risk of disease progression or death was lower with trastuzumab deruxtecan than trastuzumab emtansine [Hazard ratio - 0.28 (p<0.001)]. The corresponding overall survival rate was 94.1% and 85.9% after 12...